加味凉血消风散治疗寻常型银屑病（进行期血热证）临床疗效及作用机制研究
|
摘要
目的：本课题主要通过临床观察寻常型银屑病(进行期血热证)经加味凉血消风散治疗前后PASI评分、中医证候积分、瘙痒程度等变化,初步对此方疗效进行评价,并同时对其安全性进行评价；通过豚鼠银屑病动物模型研究此方对银屑病的作用机制,初步探讨其作用于寻常型银屑病的部分作用机制。
方法：临床研究：将60例寻常型银屑病(进行期血热证)患者随机分为加味凉血消风散组30例和复方青黛胶囊组30例,分别给予加味凉血消风散和复方青黛胶囊治疗,4周为一个疗程,连续观察2个疗程,并在治疗结束后判定疗效,同时对试验药物的安全性评价。实验研究：以5%心得安诱导型银屑病动物模型作为研究对象,主要观察实验药物对银屑病样皮损病理改变、TNF-α、PCNA作用及影响进行研究。运用放射免疫法、免疫组化等先进的实验技术和研究手段,从细胞因子、组织蛋白等方面对加味凉血消风散治疗血热证进行期寻常型银屑病的机制进行了探讨。
结果：临床观察结果显示：加味凉血消风散治疗30例血热证进行期寻常型银屑病,2个疗程后,显效22例,有效7例,无效1例,总显效率为73.33%,总有效率为96.67%。经过统计其疗效要略优于复方青黛胶囊组(Z=-2.001,P=0.045<0.05)。本试验加味凉血消风散在临床观察期间未发现任何不良反应。
实验研究结果表明：诱导型豚鼠动物模型在造模后与空白组比较均表现出银银屑病典型角化过度、角化不全等病理表现;病变组织中肿瘤坏死因子-α(TNF-α)、增殖细胞核抗原(PCNA)呈现高表达性。
经过加味凉血消风散治疗后,其耳部组织的角化程度、炎症反应等病理情况有明显改善,各中药剂量组与模型组相比较抑制角化程度均有统计学意义；高剂量中药组与模型组相比较有明显的抗炎性；总之加味凉血消风散可抑制诱导型银屑病样皮损的病理改变。
经中药组及阳性对照药物治疗后实验动物耳组织中的TNF-α的含量与模型组比较有降低趋势,其中MTX对照组与模型组有统计学意义P<0.05,高剂量组与模型组有统计学意义P<0.05,MTX对照组与低剂量组有统计学意义P<0.05。但中药高、中、低剂量之间从图表显示量效有一定的关系,但无统计学差异。
经中药组(高、中、低)以及阳性药物对照治疗后实验动物耳组织中PCNA的表达,从图示可见组间有降低趋势,中药高、中、低剂量之间虽图示量效有一定的关系,但无统计学差异。
结论：临床试验提示：加味凉血消风散治疗血热证进行期寻常型银屑病有较好的疗效和安全性；动物实验研究提示：加味凉血消风散有较好的抗炎、抑制角质形成细胞角化的作用,通过试验揭示加味凉血消风散可通过抑制TNF-α来达到抗炎、抑制角质形成细胞角化的作用。
Objective:The subject of clinical observation, mainly through the blood to heat syndrome of psoriasis vulgaris by Jia Wei Liang Xue Xiao Feng San PASI score before and after treatment, the symptom score, changes in the degree of itching, preliminary evaluation of this side effect, while its safety evaluation; through the guinea pig animal model of psoriasis psoriasis side effect of this mechanism and explore its role in psoriasis vulgaris part of the mechanisms.
Methods:Clinical study:60 cases will be carried out phase of blood-heat syndrome in patients with psoriasis vulgaris were randomly divided into flavored Jia Wei Liang Xue Xiao Feng San group of 30 cases and compound Indigo capsule group of 30 patients were given flavored cooling blood and compound Indigo Xiaofengsan capsule treatment,4 weeks for a course of treatment, continuous observation of two courses, and after treatment to determine efficacy, while during the period of the trial in the treatment of drug safety evaluation. Experimental Study:Using generally accepted 5% propranolol-induced animal models of psoriasis as an object of study, the main observation of experimental drugs on the model of lesions, TNF-a, PCNA role and impact of research. The organizational structure of the use ofradioimmunoassay, immunohistochemistry and other advanced experimental techniques and research tools, from the cellular ultrastructure, cytokines, proteins and other aspects of the organization flavored Jia Wei Liang Xue Xiao Feng San period of treatment for abnormal blood heat syndrome the mechanisms of psoriasis are discussed.
Results:The clinical observation showed that:Jia Wei Liang Xue Xiao Feng San treated 30 cases of blood-heat syndrome type to view psoriasis, two markedly after treatment in 22 cases, effective in 7 cases, ineffective in 1 case, the total effective rate was 73.33% and the total effective rate of 96.67%. Slightly better than its efficacy through statistical compound Indigo capsule group (Z=-2.001, P=0.045<0.05). This test Modified cooling blood in the clinical observation of Xiaofengsan string not found any adverse reactions.
Experimental results show that:induced animal model in guinea pigs after modeling were compared with the control group showed typical hyperkeratosis Bank of psoriasis, and other pathological manifestations of parakeratosis; diseased tissue tumor necrosis factor-α(TNF-α), proliferating cell nuclear antigen (PCNA) showed high expression.
After Modified Liangxue Xiaofengsan treatment, the ear level of the organization keratosis, inflammation and other pathological conditions have markedly improved, the medicine dose group compared with the model group were statistically significant degree of inhibition keratosis; high dose of Chinese medicine compared with the model group has obvious anti-inflammatory; short flavored Liangxue Xiaofengsan inhibit psoriasis-like lesions induced by the pathological changes.
At the same time by the Chinese group and positive control animals treated ear tissue content of TNF-αcompared with the model group decreased, and MTX control group and model group was statistically significant P<0.05, high dose group and model group statistically significant P<0.05, MTX control group and low dose group was statistically significant P<0.05. But the medicine of high, medium and low dose chart shows the dose from among a certain relationship, but not significantly.
The Chinese group (high, medium, low) and positive control animals treated ear tissue expression of PCNA, icons can be seen from the group had a lower Chinese high, medium and low doses of dose-effect between the chart shows there though certain relations, but not significantly.
Conclusion:The clinical trials Tip:Modified cooling blood Xiaofengsan period of treatment for psoriasis of blood-heat syndrome has good efficacy and safety; animal research suggests that:Modified cooling blood Xiaofengsan better anti-inflammatory, inhibit keratinocyte The role of keratinization forming cells, through the cooling blood test revealed Xiaofengsan Modified by inhibiting TNF-αto regulate the apoptosis of keratinocytes to achieve anti-inflammatory, inhibit keratinocyte keratosis role.
方法：临床研究：将60例寻常型银屑病(进行期血热证)患者随机分为加味凉血消风散组30例和复方青黛胶囊组30例,分别给予加味凉血消风散和复方青黛胶囊治疗,4周为一个疗程,连续观察2个疗程,并在治疗结束后判定疗效,同时对试验药物的安全性评价。实验研究：以5%心得安诱导型银屑病动物模型作为研究对象,主要观察实验药物对银屑病样皮损病理改变、TNF-α、PCNA作用及影响进行研究。运用放射免疫法、免疫组化等先进的实验技术和研究手段,从细胞因子、组织蛋白等方面对加味凉血消风散治疗血热证进行期寻常型银屑病的机制进行了探讨。
结果：临床观察结果显示：加味凉血消风散治疗30例血热证进行期寻常型银屑病,2个疗程后,显效22例,有效7例,无效1例,总显效率为73.33%,总有效率为96.67%。经过统计其疗效要略优于复方青黛胶囊组(Z=-2.001,P=0.045<0.05)。本试验加味凉血消风散在临床观察期间未发现任何不良反应。
实验研究结果表明：诱导型豚鼠动物模型在造模后与空白组比较均表现出银银屑病典型角化过度、角化不全等病理表现;病变组织中肿瘤坏死因子-α(TNF-α)、增殖细胞核抗原(PCNA)呈现高表达性。
经过加味凉血消风散治疗后,其耳部组织的角化程度、炎症反应等病理情况有明显改善,各中药剂量组与模型组相比较抑制角化程度均有统计学意义；高剂量中药组与模型组相比较有明显的抗炎性；总之加味凉血消风散可抑制诱导型银屑病样皮损的病理改变。
经中药组及阳性对照药物治疗后实验动物耳组织中的TNF-α的含量与模型组比较有降低趋势,其中MTX对照组与模型组有统计学意义P<0.05,高剂量组与模型组有统计学意义P<0.05,MTX对照组与低剂量组有统计学意义P<0.05。但中药高、中、低剂量之间从图表显示量效有一定的关系,但无统计学差异。
经中药组(高、中、低)以及阳性药物对照治疗后实验动物耳组织中PCNA的表达,从图示可见组间有降低趋势,中药高、中、低剂量之间虽图示量效有一定的关系,但无统计学差异。
结论：临床试验提示：加味凉血消风散治疗血热证进行期寻常型银屑病有较好的疗效和安全性；动物实验研究提示：加味凉血消风散有较好的抗炎、抑制角质形成细胞角化的作用,通过试验揭示加味凉血消风散可通过抑制TNF-α来达到抗炎、抑制角质形成细胞角化的作用。
Objective:The subject of clinical observation, mainly through the blood to heat syndrome of psoriasis vulgaris by Jia Wei Liang Xue Xiao Feng San PASI score before and after treatment, the symptom score, changes in the degree of itching, preliminary evaluation of this side effect, while its safety evaluation; through the guinea pig animal model of psoriasis psoriasis side effect of this mechanism and explore its role in psoriasis vulgaris part of the mechanisms.
Methods:Clinical study:60 cases will be carried out phase of blood-heat syndrome in patients with psoriasis vulgaris were randomly divided into flavored Jia Wei Liang Xue Xiao Feng San group of 30 cases and compound Indigo capsule group of 30 patients were given flavored cooling blood and compound Indigo Xiaofengsan capsule treatment,4 weeks for a course of treatment, continuous observation of two courses, and after treatment to determine efficacy, while during the period of the trial in the treatment of drug safety evaluation. Experimental Study:Using generally accepted 5% propranolol-induced animal models of psoriasis as an object of study, the main observation of experimental drugs on the model of lesions, TNF-a, PCNA role and impact of research. The organizational structure of the use ofradioimmunoassay, immunohistochemistry and other advanced experimental techniques and research tools, from the cellular ultrastructure, cytokines, proteins and other aspects of the organization flavored Jia Wei Liang Xue Xiao Feng San period of treatment for abnormal blood heat syndrome the mechanisms of psoriasis are discussed.
Results:The clinical observation showed that:Jia Wei Liang Xue Xiao Feng San treated 30 cases of blood-heat syndrome type to view psoriasis, two markedly after treatment in 22 cases, effective in 7 cases, ineffective in 1 case, the total effective rate was 73.33% and the total effective rate of 96.67%. Slightly better than its efficacy through statistical compound Indigo capsule group (Z=-2.001, P=0.045<0.05). This test Modified cooling blood in the clinical observation of Xiaofengsan string not found any adverse reactions.
Experimental results show that:induced animal model in guinea pigs after modeling were compared with the control group showed typical hyperkeratosis Bank of psoriasis, and other pathological manifestations of parakeratosis; diseased tissue tumor necrosis factor-α(TNF-α), proliferating cell nuclear antigen (PCNA) showed high expression.
After Modified Liangxue Xiaofengsan treatment, the ear level of the organization keratosis, inflammation and other pathological conditions have markedly improved, the medicine dose group compared with the model group were statistically significant degree of inhibition keratosis; high dose of Chinese medicine compared with the model group has obvious anti-inflammatory; short flavored Liangxue Xiaofengsan inhibit psoriasis-like lesions induced by the pathological changes.
At the same time by the Chinese group and positive control animals treated ear tissue content of TNF-αcompared with the model group decreased, and MTX control group and model group was statistically significant P<0.05, high dose group and model group statistically significant P<0.05, MTX control group and low dose group was statistically significant P<0.05. But the medicine of high, medium and low dose chart shows the dose from among a certain relationship, but not significantly.
The Chinese group (high, medium, low) and positive control animals treated ear tissue expression of PCNA, icons can be seen from the group had a lower Chinese high, medium and low doses of dose-effect between the chart shows there though certain relations, but not significantly.
Conclusion:The clinical trials Tip:Modified cooling blood Xiaofengsan period of treatment for psoriasis of blood-heat syndrome has good efficacy and safety; animal research suggests that:Modified cooling blood Xiaofengsan better anti-inflammatory, inhibit keratinocyte The role of keratinization forming cells, through the cooling blood test revealed Xiaofengsan Modified by inhibiting TNF-αto regulate the apoptosis of keratinocytes to achieve anti-inflammatory, inhibit keratinocyte keratosis role.
引文
[1]张学军,何春水,陆洪光等,皮肤性病学,北京：人民卫生出版社,2008,第7版：141-144
[2]郑筱萸。中药新药临床研究指导原则[M]北京：中国医药科技出版社,2002：299-302
[3]欧阳恒、杨志波新编中医皮肤病学北京人民卫生出版社,2000：332-338
[4]Fredriksson T,Pettersson U.Severe Psorciasis oralth erapy with a new retinoid.Dermatological.1978.157:238-240
[5]王之春,中国民间疗法,2003,11(1)：48-49
[6]张文芳,复方青黛胶囊引起肝损害1例,中国中医药信息杂志,2002,9(2)：59
[7]冯泽海、高文平、徐汉卿等,复方青黛胶囊对银屑病实验模型影响的研究,中国皮肤性病学杂志1996,10(6)：337
[8]冯捷、徐汉卿、苏保山等复方青黛胶囊对银屑病表皮角朊细胞中c-myc表达的影响中国皮肤性病学杂志1996,16(3)：146-148
[9]中医研究院广安门医院.朱仁康临床经验集[M].北京：人民卫生出版社,1979.
[10]北京中医医院.赵炳南临床经验集[M].北京：人民卫生出版社.1979.
[11]张志礼.张志礼皮肤病临床经验辑要[M].北京：中国医药科技出版社,2001
[12]顾伯华·实用中医外科学,490页。上海科学技术出版社,1985年1月第二版
[13]刘承煌·银屑病的临床和研究,上海,上海科学技术文献出版社出版,1994：151
[14]国家药典委员会.中华人民共和国药典·一部[S].北京：化学工业出版社,2005.
[15]陈赤.水牛角的研究与应用[J].广西中医学院学报,2004,7(4)：72.
[16]张少波,水牛角治疗银屑病,辽宁中医学院学报,2006,8(1)：69.
[17]韩俊艳,檀德宏,王敏伟.水牛角水解物的止血作用研究[J].实用药物与临床.2004,7(3)：17.
[18]李光华周旭贺弋等.龙骨免疫作用的实验研究.江苏中医药2003,24(4)： 54-55.
[19]董映枢,合欢皮治疗失眠小议[J]浙江中医杂志,1988,23(9)：424.
[20]戴岳,杭秉茜,孟庆玉等.女贞子的抗炎作用[J].中国中药杂志,1989,14(7)：47.
[21]黄畋,张淑芝,孙令心得安涂药造成豚鼠耳部银屑病病样病理变化,中华皮肤科杂志,1991,24(2)：96-97.
[22]闫小宁,冯捷,崔荣等.豚鼠银屑病样模型中血清TNF-α变化的实验研究.陕西医学杂志.2006,35(3)：278-280.
[23]Baker BS, Swain A F Fry L, et al. Epidermal T lymphocytes and HLA-DR expression in psoriasis[J]. Br J Dermatol,1984,1 10(5):555-564.
[24]Bowcock AM, Krueger JG. Getting under the skin:the immunogenetics of psoriasis[J].Nat Rev Immunol,2005,5(9):699-711.
[25]赵辨.临床皮肤病学.第3版[M]南京：江苏科学技术出版社,2001,759-761.
[26]欧阳恒,杨志波.银屑病的诊断与治疗[M]人民军医出版社,2001.
[27]邵长庚.我国银屑病的流行和防治现状[J].中华皮肤科杂志,1996,29(2)：75.
[28]窦海中银屑病临床治疗体会浙江中医杂志2002,12：522.
[29]Feldman SR, Menter A, Koo JY. Improved health- related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis [J]. Br J Dermatol,2004,150(2):317-326.
[30]Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis[J]. Br J Dermatol, 2003,149(2):318-322..
[31]张敏,汪盛,张谊之等.银屑病患者生活质量调查[J].临床皮肤杂志,2006,35(6)：370-372.
[32]韩钢文,汤占利,朱学骏.银屑病治疗展望[J].国外医学皮肤性病学分册,2002,28(5)：316-318.
[33]邵长庚.银屑病治疗历史的回顾和展望[J].中华医学研究杂志,2006,6(10)：1081-1083.
[34]Nickoloff B J. Keratinocytes regain momentum as instigatorsof cutaneous inflammation[J]. Trends Mol Med,2006,12(3):102-106.
[35]Ziboh V A, Hsia S I. Effects of prostaglandin E2 on rat skin:inhibition of sterol ester biosynthesis and clearing of scaly le-sions in essential fatty acid deficiency[J]. J 1. ipid Res,1972,13(4):458-467.
[36]Gaylarde PM, Brock AP. Sarkany 1. Psoriasiform chan ges in guinea pig skin from propranolol. Clin Exp Dermatol[J] 1978,3(2):157-160.
[37]袁冰、余洪生、秦丽影,甲氨喋呤治疗银屑病的临床观察,中华临床医学研究杂志,2005,11(8)：1133-1134.
[38]郝小军、冯兰珍、陈艳等,复方甘草酸苷联合甲氨喋呤治疗中重度银屑病疗效观察,岭南皮肤性病科杂志,2007,14(4)：215-216.
[39]冯冬梅、郑学军、周向昭等甲氨喋呤对斑块状银屑病治疗前后TNF-α、IL-6的影响及其作用机制探讨,河北北方学院学报,2007,24(3)：38-39.
[40]李常兴,张锡宝,吴志华,甲氨喋呤与银屑病,岭南皮肤性病科杂志,2004.11(2)：200-203.
[41]常兴,张锡宝,吴志华等,甲氨喋呤对银屑病患者皮损内VEGFmRNA影响的研究,中国皮肤性病学杂志,2005,19(9)：522-524.
[42]Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epiderm is in skin disorders with dermal neutr ophilicinfiltration:interleuk in 21 beta and tumournecrosis factor-alpha stimulate its secretion invitro[J]. B r J Dermato 1; 2000, 143(4):728
[43]Gisondi P, Gubinelli E, Cocuroccia B, et al. Targeting TumorNecrosis Factor alpha in the Therapy of Psoriasis[J]. CurrDrugTargets Inflamm Allergy,2004,3 (2): 175-183.
[44]Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology oftumor necrosis factor - alpha - imp lications for p soriasis[J]. ExpDermatol,2004,13 (4):193-222.
[45]Kristensen M, Chu CQ, Eedy DJ, et al. Localization of tumournecrosis factor alpha (TNF - alpha) and its recep tors in normaland p soriatic skin:ep idermal cells exp ress the 55 - kD but not the75 - kD TNF recep tor[J]. Clin Exp Immunol,1993, 94 (2):354-362.
[46]Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safetyof infliximab monotherapy for p laque - type p soriasis:a random2ised trial[J].Lancet,2001,357 (9271):1842-1847.
[47]Bonifati C,carducci M, Cordiali-Fei P,et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factorlevels in suction blister fluids and sera of psoriatic patients-relationship with disease severity[J]. ClinExp Dermatoltl994,19(5):383.
[48]范团起,李卫红,IL-6及TNF-α与寻常性银屑病的关系,医药论坛杂志,2006,27(12)：34、37.
[49]张春红,杜锡贤,张春敏等,进行期寻常型银屑病患者血清TNF-α和IL-8水平检测中国麻风皮肤病杂志,2005,21(2)：101-102.
[50]高奎斌刘继峰王雅坤等寻常型银屑病患者皮损表皮TNFa受体及其mRNA的表达中国免疫学杂志2004,20(6)：426-428.
[51]高慧王琴李瑞琴等TNF-α对小鼠银屑病模型的实验研究皮肤病与性病2005,27(3)：6-7.
[52]周海燕.中性粒细胞在诱导银屑病急性炎症中的作用.国外医学皮肤性病学分册,2001；27(3)：170.
[53]张敏,张谊之汪盛,等.树突状细胞、自然杀伤细胞和粘附分子在银屑病发病中的作用.四川大学学报(医学版),2004；35(5)：626.
[54]陈先进张开明尹国华等.肿瘤坏死因子-α对角质形成细胞产生白介素8和增殖活性的影响.中华皮肤科杂志；2002；35(4)：293.
[55]Pfundt R, W ingens M, Bergers M, et al. TNF-α and serum induce SKAIP/elafin gene expression in human keratincytes by p38 MAP kinase-dependent pathway[J]. Arch Dermato/Rues,2000,292(4):180-187.
[56]Weinstein GD, t P. Methotrexate for psoriasis, A newtherapeutic schedule. Arch Dermatol,1971,103(1):33-38.
[57]Primka EJ 3rd, Colllisa C, Methotrexate-induced toxic epi-dermal necmlysis in a patient with psoriasis. J Am Acad Dermatol,1997,36(5 Pt 2):815-818.
[58]张锡宝,彭振辉,曹振平,MIX对正常人表皮角质形成细胞体外培养增殖的作用及影响.中国皮肤性病学杂志,2003,17(6)：371-373.
[59]Kelman Z. PCNA:structure, functions and interacti-ons[J]. Oncogene,1997, 14,629-640.
[60]Morrow PW,TungHY'HemmingsHC Jr. Rapamyc-in causes activation ofprotein phosphatase-2A1 an d nucear transloea tion of PCNA in CD4 + T cells[J]. Bioc hem Biophys Res Commun,2001,323:645-651
[61]Celis JE, Madsen Celis A, et al, Cyclin (PCNA, all-xiliary protein of DNApolymerase delta)is a central component of the pathway(s)leading to DNAreplication and cell division[J]. FEBS Lett,1987,220:1-7.
[62]李晓光,于肖鹏,赵海兰,等.PCNA在口腔鳞癌中的表达及其临床意义[J].泰山医学院学报,2005,26(1)：20-22.
[63]樊利芳,刁路明,陈德基,等.肺癌组织中缺氧诱导因子-1α的表达及其与凋亡和增殖的关系[J].癌症,2002,21(3)254—258.
[64]刘丹亚、苏宝山、徐汉卿等EGF-R PCNA及P53基因在银屑病皮损中的表达中国皮肤性病学杂志19961O(5)：265-266.
[65]张敏 李俸嫒 银屑病皮损区c-myc、 c-jun、 Ki-67、 PCNA、 VEGF的表达。华西医科大学学报2002 33(3)427-430.
[1]Odom RB, James WD. Berger. TGAndrews'diseases of the skin clinical dermatology, edition, American, Harcourt pudlisher limited 2000;218.
[2]Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epiderm is in skin disorders with dermal neutrophilic infiltration:interleuk in- beta and tumournecrosis factor-alpha st imulate its secret ion in vit ro[J]. B r J Dermato 1; 2000,143(4):728
[3]Gisondi P, Gubinelli E, Cocuroccia B, et al. Targeting Tumor Necrosis Factor - alpha in the Therapy of Psoriasis[J]. CurrDrugTargets Inflamm Allergy,2004,3 (2):175-183.
[4]Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor - alpha - imp lications for p soriasis[J]. ExpDermatol, 2004,13 (4):193-222.
[5]刘骅,金涌TNF-α在银屑病的发病及治疗中的研究进展安徽医药 2006,10(5)：321.
[6]Kristensen M, Chu CQ, Eedy DJ, et al. Localization of tumournecrosis factor - alpha (TNF - alpha) and its recep tors in normaland p soriatic skin:ep idermal cells express the 55 - kD but not the75 - kD TNF recep tor [J]. Clin Exp Immunol,1993,94 (2):354-362.
[7]Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safetyof infliximab monotherapy for plaque - type psoriasis:a random2ised trial[J]. Lancet,2001,357 (9271):1842-1847.
[8]周海燕.中性粒细胞在诱导银屑病急性炎症中的作用.国外医学皮肤性病学分册,2001,27(3)：170.
[9]张敏,张谊之汪盛等.树突状细胞、自然杀伤细胞和粘附分子在银屑病发病中的作用.四川大学学报(医学版),2004;35(5)：626.
[10]陈先进,张开明,尹国华,等.肿瘤坏死因子-α对角质形成细胞产生白介素8和增殖活性的影响.中华皮肤科杂志;2002;35(4) ：293.
[11]KristensenM, ChuCQ, EedyDJ, et al. Localization of tumour necrosis factor-alpha(TNF - α)and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor[J]. Clin Exp Immunol,1993,94(2):354-362.
[12]范团起,李卫红,IL-6及TNF-α与寻常性银屑病的关系,医药论坛杂志,2006,27(12)：34-37
[13]张春红,杜锡贤,张春敏等,进行期寻常型银屑病患者血清TNF-α和工L-8水平检测中国麻风皮肤病杂志,2005,21(2)：101-102.
[14]高奎斌,刘继峰,王雅坤等寻常型银屑病患者皮损表皮TNFa受体及其mRNA的 表达中国免疫学杂志2004,20(6)：426-428.
[15]高奎斌李久宏赵雨杰等银屑病患者皮损和血清TNF-α受体P55检测及其意义中国麻风皮肤病杂志2004,20(3)：205-207
[16]高奎斌、刘继峰、赵雨杰等寻常型银屑病患者皮损表皮TNF-α受体p75的表达及其意义.中华微生物学和免疫学杂志.2003,23(7)：521
[17]彭振辉,张美芳,张秉正,等.银屑病中医分型血清TGF-B、TNF-α的生物测定[J].中国皮肤性病学杂志,2000,14(1)：2
[18]程滨珠.银屑病患者血清肿瘤坏死因子水平与中医证型关系的初步研究[J].中国中医基础医学杂志,1999,5(9)：42—43.
[19]谢转,王爱学.中西医结合治疗银屑病疗效观察.现代中西医结合杂志2005；14：2680.
[20]史立宏李晓民张秀荣等黄芪对寻常型银屑病患者血浆TNF-α及IFN-γ的影响,中国麻风皮肤病杂志,2007,23(6)：525.
[21]邓俐,张堂德,杜江.商陆皂苷甲对银屑病患者外周血单个核细胞产生肿瘤坏死因子和可溶性白介素2受体的影响[J].临床皮肤科杂志,2004,33(7)：407-409.
[22]万屏,肖农,朱明华,等.昆明山海棠对人单核细胞TNF-α、IL—8及基因表达的影响[J].临床皮肤科杂志,2007,31(1)：3-5.
[23]王萍,张芄,李伟凡,等.凉血活血汤治疗寻常性银屑病工临床观察及TNF-α水平检测[J].中国皮肤性病学杂志,2001,15(2)：90-91.
[24]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿瘤坏死因子和白细胞介素8水平检测[J].临床皮肤科杂志,2002,31(12)：770-771.
[25]张春红,杜锡贤,张春敏,等.土苓饮治疗进行期寻常型银屑病临床研究[J].山东中医药大学学报,2004,28(6)：440-442.
[26]单筠筠,宋秀祖,尉晓冬,等.银屑Ⅰ号治疗寻常性银屑病临床疗效观察及相关细胞因子检测[J].中国中西医结合皮肤性病学杂志,2006,5(2)：87—88.
[1]范瑞强,廖元兴.中西医结合临床皮肤性病学[M].广州：世界图书出版公司,2003.616.
[2]Qin WZ. Studies on treatment of psoriasis with integrative medicineⅢ. Chinese Journal of Integrative Medicine,2002,8:248-25。
[3]Bonifati C, Ameglio F. Cytokines in psoriasis[J]. Int J Dermatol,1999,38: 241-251.
[4]路又璐,秦建中.17味中药对培养的表皮细胞增殖的影响.临床皮肤科杂志1996；(4)：202
[5]黄青、瞿幸、吴清黄连、土大黄、苍术提取液抗银屑病实验研究,中国中医药信息杂志,2008,15(6)：30-31
[6]冯泽海,高文平,徐汉卿,等.复方青黛胶囊对银屑病实验模型影响的研究.中国皮肤性病学杂志1996；10(6)：337
[7]王琼玉、刘平、张爱军等复方青黛饮对角质形成细胞增殖影响的实验研究.实用医学杂,2006,22(15)：1720-1721
[8]姜相德,李进,等.银屑灵涂膜剂治疗银屑病的实验研究[J]’天津医药、2002,19(5)：39-41
[9]刘晓明,孙秀坤,齐欣,等.20种中药灌胃对小鼠上皮细胞增殖和表皮细胞分化及血浆内皮素.1的影响.中华皮肤科杂志.2001.34(4)：282-283
[10]白英华,田静,金春林凉血四根提取物对实验性鼠阴道上皮细胞过度增殖的影响.中国中西医结合皮肤性病学杂志,2006,5(3)：144
[11]王禾,孙丽蕴,邓丙戌,等.紫草素、靛玉红对角质形成细胞凋亡的影响.中国麻风皮肤病杂志,2003,19(4)：325
[12]周利平,杨木兰,江涛,等.银屑病惠者Fas和Bcl-2的表达及中药的作用.中华皮肤科杂志,2002,35(2)：146
[13]田静刘永斌滋阴除湿汤对银屑病患者促细胞凋亡相关基因Fas bax表达的影响辽宁中医杂志2008年第35卷第10期：1449
[14]邓俐,张堂德,杜江.商陆皂苷甲对银屑病患者外周血单个核细胞产生α肿瘤坏死因子和可溶性白介素2受体的影响[J].临床皮肤科杂志,2004,33(7)：407—-409.
[15]单筠筠,宋秀祖,尉晓冬,等.银屑Ⅰ号治疗寻常性银屑病Ⅰ临床疗效观察及相关细胞因子检测[J].中国中西医结合皮肤性病学杂志,2006,5(2)：87—88.
[16]张云璧,瞿幸,牛福玲.常用治疗银屑病的中药对肿瘤坏死因子α刺激后角质形成细胞生长及分泌白介素8的影响.中国中西医结合皮肤性病学杂志,2006,5(1)： 19
[17]范斌,李斌,沈健雄,等.凉血和活血中药对银屑病患者不同时期细胞因子的影响[J]. 中国中西医结合皮肤性病学杂志,2006,5(2)：70—71
[18]陈孙孝,温海,邓安梅,等.银屑病患者淋巴细胞及细胞因子在发病机制中的作用[J]. 中国免疫学杂志,2002,18：207—-209.
[19]陈红、王思平.复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响[J].中药材,2004,27(11)：885—886.
[20]娄卫海,张志礼,邓丙戌,等.凉血活血汤治疗进行期银屑病的临床及实验研究[J]. 中华皮肤科杂志1999,32(2)：80—81.
[21]Redisch W. Messina H, Hughes G, McEwen C, CapillaroseopieObse-rvations in rheumatic diseases. Ann Rheitm Dis 1970:29:244-53
[22]曹越兰,孙国均,卢兴国.银屑病患者血栓调节蛋白及血液流变学检测.中华皮肤科杂志,2000,33(2)：113
[23]A. Go'rnicki. Changes in erythrocyte microrheology in patients with psoriasis.2004 Blackwell Publishing Ltd. Clinical and Experimental Dermatology,29,67-70。
[24]肖青林,司本辉,吴康智,等.不同剂量丹参治疗银屑病患者后血液流变学改变[J].中华皮肤科杂志,2000,33(6)：414-415.
[25]李炎夏,周起云,王景学,等.黄芪维胺酯连联合应用对银屑病甲襞微循环的影响[J].中国皮肤性病学杂志,1998,12(6)：345-346.
[26]肖青林,常开齐,司本辉,等.银肤欣系列治疗寻常型银屑病的临床研究[J].天津中医,2000,17(2)：20—22
[27]邱实,谭升顺,孙治平.活血散瘀消银汤治疗寻常型银屑病血瘀证的临床研究[J].中药材,2005,28(5)：442-444.
[28]王雅娟.石景伟,董西林.紫草活血汤治疗银屑病的疗效及对血液流变学的影响,西安交通大学学报(医学版),2003,24(3)：276
[29]齐凤琴、姜淑凤、富学东增液消银汤对银屑病患者神经肽水平的影响中国煤炭工业医学杂志2007年9月第10卷第9期：1071
[30]钱方,杨志波,欧阳恒.竹黄颗粒剂Ⅱ号对降钙素基因相关肽的影响[J].湖南中医药导报,2004,10(12)：54—55,59
[31]杨志波、欧阳恒、许斌竹黄颗粒剂Ⅱ号对银屑病患者β-内啡肽的影响中国中西医结合皮肤性病学杂志2003年第2卷第3期166-167。
[32]Werner S, Smola H. Paracrine regulation of keratinocyte proliferationand differentiationm. TrendsCenBiol,2001,11:143-146.
[33]Wu SX, Guo NR. Clinical observation on effect of tfiptolide tablet intreating patients with psoriasis vulgaris[J]. Chinese Journal of IntegrativeMedicine,2005, 11：147-1481。
[34]王砚宁,毕新岭,顾军,等.黄芩甙治疗银屑病的机制研究[J].中国中西医结合皮肤性病学杂志,2003,2(4)：209—211.
[35]毕新岭,王砚宁,顾军,等.黄芩甙对成纤维细胞iNOS表达的影响[J].中国中西医结合皮肤性病学杂志,2003,2(3)：152—154
[2]郑筱萸。中药新药临床研究指导原则[M]北京：中国医药科技出版社,2002：299-302
[3]欧阳恒、杨志波新编中医皮肤病学北京人民卫生出版社,2000：332-338
[4]Fredriksson T,Pettersson U.Severe Psorciasis oralth erapy with a new retinoid.Dermatological.1978.157:238-240
[5]王之春,中国民间疗法,2003,11(1)：48-49
[6]张文芳,复方青黛胶囊引起肝损害1例,中国中医药信息杂志,2002,9(2)：59
[7]冯泽海、高文平、徐汉卿等,复方青黛胶囊对银屑病实验模型影响的研究,中国皮肤性病学杂志1996,10(6)：337
[8]冯捷、徐汉卿、苏保山等复方青黛胶囊对银屑病表皮角朊细胞中c-myc表达的影响中国皮肤性病学杂志1996,16(3)：146-148
[9]中医研究院广安门医院.朱仁康临床经验集[M].北京：人民卫生出版社,1979.
[10]北京中医医院.赵炳南临床经验集[M].北京：人民卫生出版社.1979.
[11]张志礼.张志礼皮肤病临床经验辑要[M].北京：中国医药科技出版社,2001
[12]顾伯华·实用中医外科学,490页。上海科学技术出版社,1985年1月第二版
[13]刘承煌·银屑病的临床和研究,上海,上海科学技术文献出版社出版,1994：151
[14]国家药典委员会.中华人民共和国药典·一部[S].北京：化学工业出版社,2005.
[15]陈赤.水牛角的研究与应用[J].广西中医学院学报,2004,7(4)：72.
[16]张少波,水牛角治疗银屑病,辽宁中医学院学报,2006,8(1)：69.
[17]韩俊艳,檀德宏,王敏伟.水牛角水解物的止血作用研究[J].实用药物与临床.2004,7(3)：17.
[18]李光华周旭贺弋等.龙骨免疫作用的实验研究.江苏中医药2003,24(4)： 54-55.
[19]董映枢,合欢皮治疗失眠小议[J]浙江中医杂志,1988,23(9)：424.
[20]戴岳,杭秉茜,孟庆玉等.女贞子的抗炎作用[J].中国中药杂志,1989,14(7)：47.
[21]黄畋,张淑芝,孙令心得安涂药造成豚鼠耳部银屑病病样病理变化,中华皮肤科杂志,1991,24(2)：96-97.
[22]闫小宁,冯捷,崔荣等.豚鼠银屑病样模型中血清TNF-α变化的实验研究.陕西医学杂志.2006,35(3)：278-280.
[23]Baker BS, Swain A F Fry L, et al. Epidermal T lymphocytes and HLA-DR expression in psoriasis[J]. Br J Dermatol,1984,1 10(5):555-564.
[24]Bowcock AM, Krueger JG. Getting under the skin:the immunogenetics of psoriasis[J].Nat Rev Immunol,2005,5(9):699-711.
[25]赵辨.临床皮肤病学.第3版[M]南京：江苏科学技术出版社,2001,759-761.
[26]欧阳恒,杨志波.银屑病的诊断与治疗[M]人民军医出版社,2001.
[27]邵长庚.我国银屑病的流行和防治现状[J].中华皮肤科杂志,1996,29(2)：75.
[28]窦海中银屑病临床治疗体会浙江中医杂志2002,12：522.
[29]Feldman SR, Menter A, Koo JY. Improved health- related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis [J]. Br J Dermatol,2004,150(2):317-326.
[30]Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis[J]. Br J Dermatol, 2003,149(2):318-322..
[31]张敏,汪盛,张谊之等.银屑病患者生活质量调查[J].临床皮肤杂志,2006,35(6)：370-372.
[32]韩钢文,汤占利,朱学骏.银屑病治疗展望[J].国外医学皮肤性病学分册,2002,28(5)：316-318.
[33]邵长庚.银屑病治疗历史的回顾和展望[J].中华医学研究杂志,2006,6(10)：1081-1083.
[34]Nickoloff B J. Keratinocytes regain momentum as instigatorsof cutaneous inflammation[J]. Trends Mol Med,2006,12(3):102-106.
[35]Ziboh V A, Hsia S I. Effects of prostaglandin E2 on rat skin:inhibition of sterol ester biosynthesis and clearing of scaly le-sions in essential fatty acid deficiency[J]. J 1. ipid Res,1972,13(4):458-467.
[36]Gaylarde PM, Brock AP. Sarkany 1. Psoriasiform chan ges in guinea pig skin from propranolol. Clin Exp Dermatol[J] 1978,3(2):157-160.
[37]袁冰、余洪生、秦丽影,甲氨喋呤治疗银屑病的临床观察,中华临床医学研究杂志,2005,11(8)：1133-1134.
[38]郝小军、冯兰珍、陈艳等,复方甘草酸苷联合甲氨喋呤治疗中重度银屑病疗效观察,岭南皮肤性病科杂志,2007,14(4)：215-216.
[39]冯冬梅、郑学军、周向昭等甲氨喋呤对斑块状银屑病治疗前后TNF-α、IL-6的影响及其作用机制探讨,河北北方学院学报,2007,24(3)：38-39.
[40]李常兴,张锡宝,吴志华,甲氨喋呤与银屑病,岭南皮肤性病科杂志,2004.11(2)：200-203.
[41]常兴,张锡宝,吴志华等,甲氨喋呤对银屑病患者皮损内VEGFmRNA影响的研究,中国皮肤性病学杂志,2005,19(9)：522-524.
[42]Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epiderm is in skin disorders with dermal neutr ophilicinfiltration:interleuk in 21 beta and tumournecrosis factor-alpha stimulate its secretion invitro[J]. B r J Dermato 1; 2000, 143(4):728
[43]Gisondi P, Gubinelli E, Cocuroccia B, et al. Targeting TumorNecrosis Factor alpha in the Therapy of Psoriasis[J]. CurrDrugTargets Inflamm Allergy,2004,3 (2): 175-183.
[44]Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology oftumor necrosis factor - alpha - imp lications for p soriasis[J]. ExpDermatol,2004,13 (4):193-222.
[45]Kristensen M, Chu CQ, Eedy DJ, et al. Localization of tumournecrosis factor alpha (TNF - alpha) and its recep tors in normaland p soriatic skin:ep idermal cells exp ress the 55 - kD but not the75 - kD TNF recep tor[J]. Clin Exp Immunol,1993, 94 (2):354-362.
[46]Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safetyof infliximab monotherapy for p laque - type p soriasis:a random2ised trial[J].Lancet,2001,357 (9271):1842-1847.
[47]Bonifati C,carducci M, Cordiali-Fei P,et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factorlevels in suction blister fluids and sera of psoriatic patients-relationship with disease severity[J]. ClinExp Dermatoltl994,19(5):383.
[48]范团起,李卫红,IL-6及TNF-α与寻常性银屑病的关系,医药论坛杂志,2006,27(12)：34、37.
[49]张春红,杜锡贤,张春敏等,进行期寻常型银屑病患者血清TNF-α和IL-8水平检测中国麻风皮肤病杂志,2005,21(2)：101-102.
[50]高奎斌刘继峰王雅坤等寻常型银屑病患者皮损表皮TNFa受体及其mRNA的表达中国免疫学杂志2004,20(6)：426-428.
[51]高慧王琴李瑞琴等TNF-α对小鼠银屑病模型的实验研究皮肤病与性病2005,27(3)：6-7.
[52]周海燕.中性粒细胞在诱导银屑病急性炎症中的作用.国外医学皮肤性病学分册,2001；27(3)：170.
[53]张敏,张谊之汪盛,等.树突状细胞、自然杀伤细胞和粘附分子在银屑病发病中的作用.四川大学学报(医学版),2004；35(5)：626.
[54]陈先进张开明尹国华等.肿瘤坏死因子-α对角质形成细胞产生白介素8和增殖活性的影响.中华皮肤科杂志；2002；35(4)：293.
[55]Pfundt R, W ingens M, Bergers M, et al. TNF-α and serum induce SKAIP/elafin gene expression in human keratincytes by p38 MAP kinase-dependent pathway[J]. Arch Dermato/Rues,2000,292(4):180-187.
[56]Weinstein GD, t P. Methotrexate for psoriasis, A newtherapeutic schedule. Arch Dermatol,1971,103(1):33-38.
[57]Primka EJ 3rd, Colllisa C, Methotrexate-induced toxic epi-dermal necmlysis in a patient with psoriasis. J Am Acad Dermatol,1997,36(5 Pt 2):815-818.
[58]张锡宝,彭振辉,曹振平,MIX对正常人表皮角质形成细胞体外培养增殖的作用及影响.中国皮肤性病学杂志,2003,17(6)：371-373.
[59]Kelman Z. PCNA:structure, functions and interacti-ons[J]. Oncogene,1997, 14,629-640.
[60]Morrow PW,TungHY'HemmingsHC Jr. Rapamyc-in causes activation ofprotein phosphatase-2A1 an d nucear transloea tion of PCNA in CD4 + T cells[J]. Bioc hem Biophys Res Commun,2001,323:645-651
[61]Celis JE, Madsen Celis A, et al, Cyclin (PCNA, all-xiliary protein of DNApolymerase delta)is a central component of the pathway(s)leading to DNAreplication and cell division[J]. FEBS Lett,1987,220:1-7.
[62]李晓光,于肖鹏,赵海兰,等.PCNA在口腔鳞癌中的表达及其临床意义[J].泰山医学院学报,2005,26(1)：20-22.
[63]樊利芳,刁路明,陈德基,等.肺癌组织中缺氧诱导因子-1α的表达及其与凋亡和增殖的关系[J].癌症,2002,21(3)254—258.
[64]刘丹亚、苏宝山、徐汉卿等EGF-R PCNA及P53基因在银屑病皮损中的表达中国皮肤性病学杂志19961O(5)：265-266.
[65]张敏 李俸嫒 银屑病皮损区c-myc、 c-jun、 Ki-67、 PCNA、 VEGF的表达。华西医科大学学报2002 33(3)427-430.
[1]Odom RB, James WD. Berger. TGAndrews'diseases of the skin clinical dermatology, edition, American, Harcourt pudlisher limited 2000;218.
[2]Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epiderm is in skin disorders with dermal neutrophilic infiltration:interleuk in- beta and tumournecrosis factor-alpha st imulate its secret ion in vit ro[J]. B r J Dermato 1; 2000,143(4):728
[3]Gisondi P, Gubinelli E, Cocuroccia B, et al. Targeting Tumor Necrosis Factor - alpha in the Therapy of Psoriasis[J]. CurrDrugTargets Inflamm Allergy,2004,3 (2):175-183.
[4]Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor - alpha - imp lications for p soriasis[J]. ExpDermatol, 2004,13 (4):193-222.
[5]刘骅,金涌TNF-α在银屑病的发病及治疗中的研究进展安徽医药 2006,10(5)：321.
[6]Kristensen M, Chu CQ, Eedy DJ, et al. Localization of tumournecrosis factor - alpha (TNF - alpha) and its recep tors in normaland p soriatic skin:ep idermal cells express the 55 - kD but not the75 - kD TNF recep tor [J]. Clin Exp Immunol,1993,94 (2):354-362.
[7]Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safetyof infliximab monotherapy for plaque - type psoriasis:a random2ised trial[J]. Lancet,2001,357 (9271):1842-1847.
[8]周海燕.中性粒细胞在诱导银屑病急性炎症中的作用.国外医学皮肤性病学分册,2001,27(3)：170.
[9]张敏,张谊之汪盛等.树突状细胞、自然杀伤细胞和粘附分子在银屑病发病中的作用.四川大学学报(医学版),2004;35(5)：626.
[10]陈先进,张开明,尹国华,等.肿瘤坏死因子-α对角质形成细胞产生白介素8和增殖活性的影响.中华皮肤科杂志;2002;35(4) ：293.
[11]KristensenM, ChuCQ, EedyDJ, et al. Localization of tumour necrosis factor-alpha(TNF - α)and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor[J]. Clin Exp Immunol,1993,94(2):354-362.
[12]范团起,李卫红,IL-6及TNF-α与寻常性银屑病的关系,医药论坛杂志,2006,27(12)：34-37
[13]张春红,杜锡贤,张春敏等,进行期寻常型银屑病患者血清TNF-α和工L-8水平检测中国麻风皮肤病杂志,2005,21(2)：101-102.
[14]高奎斌,刘继峰,王雅坤等寻常型银屑病患者皮损表皮TNFa受体及其mRNA的 表达中国免疫学杂志2004,20(6)：426-428.
[15]高奎斌李久宏赵雨杰等银屑病患者皮损和血清TNF-α受体P55检测及其意义中国麻风皮肤病杂志2004,20(3)：205-207
[16]高奎斌、刘继峰、赵雨杰等寻常型银屑病患者皮损表皮TNF-α受体p75的表达及其意义.中华微生物学和免疫学杂志.2003,23(7)：521
[17]彭振辉,张美芳,张秉正,等.银屑病中医分型血清TGF-B、TNF-α的生物测定[J].中国皮肤性病学杂志,2000,14(1)：2
[18]程滨珠.银屑病患者血清肿瘤坏死因子水平与中医证型关系的初步研究[J].中国中医基础医学杂志,1999,5(9)：42—43.
[19]谢转,王爱学.中西医结合治疗银屑病疗效观察.现代中西医结合杂志2005；14：2680.
[20]史立宏李晓民张秀荣等黄芪对寻常型银屑病患者血浆TNF-α及IFN-γ的影响,中国麻风皮肤病杂志,2007,23(6)：525.
[21]邓俐,张堂德,杜江.商陆皂苷甲对银屑病患者外周血单个核细胞产生肿瘤坏死因子和可溶性白介素2受体的影响[J].临床皮肤科杂志,2004,33(7)：407-409.
[22]万屏,肖农,朱明华,等.昆明山海棠对人单核细胞TNF-α、IL—8及基因表达的影响[J].临床皮肤科杂志,2007,31(1)：3-5.
[23]王萍,张芄,李伟凡,等.凉血活血汤治疗寻常性银屑病工临床观察及TNF-α水平检测[J].中国皮肤性病学杂志,2001,15(2)：90-91.
[24]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿瘤坏死因子和白细胞介素8水平检测[J].临床皮肤科杂志,2002,31(12)：770-771.
[25]张春红,杜锡贤,张春敏,等.土苓饮治疗进行期寻常型银屑病临床研究[J].山东中医药大学学报,2004,28(6)：440-442.
[26]单筠筠,宋秀祖,尉晓冬,等.银屑Ⅰ号治疗寻常性银屑病临床疗效观察及相关细胞因子检测[J].中国中西医结合皮肤性病学杂志,2006,5(2)：87—88.
[1]范瑞强,廖元兴.中西医结合临床皮肤性病学[M].广州：世界图书出版公司,2003.616.
[2]Qin WZ. Studies on treatment of psoriasis with integrative medicineⅢ. Chinese Journal of Integrative Medicine,2002,8:248-25。
[3]Bonifati C, Ameglio F. Cytokines in psoriasis[J]. Int J Dermatol,1999,38: 241-251.
[4]路又璐,秦建中.17味中药对培养的表皮细胞增殖的影响.临床皮肤科杂志1996；(4)：202
[5]黄青、瞿幸、吴清黄连、土大黄、苍术提取液抗银屑病实验研究,中国中医药信息杂志,2008,15(6)：30-31
[6]冯泽海,高文平,徐汉卿,等.复方青黛胶囊对银屑病实验模型影响的研究.中国皮肤性病学杂志1996；10(6)：337
[7]王琼玉、刘平、张爱军等复方青黛饮对角质形成细胞增殖影响的实验研究.实用医学杂,2006,22(15)：1720-1721
[8]姜相德,李进,等.银屑灵涂膜剂治疗银屑病的实验研究[J]’天津医药、2002,19(5)：39-41
[9]刘晓明,孙秀坤,齐欣,等.20种中药灌胃对小鼠上皮细胞增殖和表皮细胞分化及血浆内皮素.1的影响.中华皮肤科杂志.2001.34(4)：282-283
[10]白英华,田静,金春林凉血四根提取物对实验性鼠阴道上皮细胞过度增殖的影响.中国中西医结合皮肤性病学杂志,2006,5(3)：144
[11]王禾,孙丽蕴,邓丙戌,等.紫草素、靛玉红对角质形成细胞凋亡的影响.中国麻风皮肤病杂志,2003,19(4)：325
[12]周利平,杨木兰,江涛,等.银屑病惠者Fas和Bcl-2的表达及中药的作用.中华皮肤科杂志,2002,35(2)：146
[13]田静刘永斌滋阴除湿汤对银屑病患者促细胞凋亡相关基因Fas bax表达的影响辽宁中医杂志2008年第35卷第10期：1449
[14]邓俐,张堂德,杜江.商陆皂苷甲对银屑病患者外周血单个核细胞产生α肿瘤坏死因子和可溶性白介素2受体的影响[J].临床皮肤科杂志,2004,33(7)：407—-409.
[15]单筠筠,宋秀祖,尉晓冬,等.银屑Ⅰ号治疗寻常性银屑病Ⅰ临床疗效观察及相关细胞因子检测[J].中国中西医结合皮肤性病学杂志,2006,5(2)：87—88.
[16]张云璧,瞿幸,牛福玲.常用治疗银屑病的中药对肿瘤坏死因子α刺激后角质形成细胞生长及分泌白介素8的影响.中国中西医结合皮肤性病学杂志,2006,5(1)： 19
[17]范斌,李斌,沈健雄,等.凉血和活血中药对银屑病患者不同时期细胞因子的影响[J]. 中国中西医结合皮肤性病学杂志,2006,5(2)：70—71
[18]陈孙孝,温海,邓安梅,等.银屑病患者淋巴细胞及细胞因子在发病机制中的作用[J]. 中国免疫学杂志,2002,18：207—-209.
[19]陈红、王思平.复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响[J].中药材,2004,27(11)：885—886.
[20]娄卫海,张志礼,邓丙戌,等.凉血活血汤治疗进行期银屑病的临床及实验研究[J]. 中华皮肤科杂志1999,32(2)：80—81.
[21]Redisch W. Messina H, Hughes G, McEwen C, CapillaroseopieObse-rvations in rheumatic diseases. Ann Rheitm Dis 1970:29:244-53
[22]曹越兰,孙国均,卢兴国.银屑病患者血栓调节蛋白及血液流变学检测.中华皮肤科杂志,2000,33(2)：113
[23]A. Go'rnicki. Changes in erythrocyte microrheology in patients with psoriasis.2004 Blackwell Publishing Ltd. Clinical and Experimental Dermatology,29,67-70。
[24]肖青林,司本辉,吴康智,等.不同剂量丹参治疗银屑病患者后血液流变学改变[J].中华皮肤科杂志,2000,33(6)：414-415.
[25]李炎夏,周起云,王景学,等.黄芪维胺酯连联合应用对银屑病甲襞微循环的影响[J].中国皮肤性病学杂志,1998,12(6)：345-346.
[26]肖青林,常开齐,司本辉,等.银肤欣系列治疗寻常型银屑病的临床研究[J].天津中医,2000,17(2)：20—22
[27]邱实,谭升顺,孙治平.活血散瘀消银汤治疗寻常型银屑病血瘀证的临床研究[J].中药材,2005,28(5)：442-444.
[28]王雅娟.石景伟,董西林.紫草活血汤治疗银屑病的疗效及对血液流变学的影响,西安交通大学学报(医学版),2003,24(3)：276
[29]齐凤琴、姜淑凤、富学东增液消银汤对银屑病患者神经肽水平的影响中国煤炭工业医学杂志2007年9月第10卷第9期：1071
[30]钱方,杨志波,欧阳恒.竹黄颗粒剂Ⅱ号对降钙素基因相关肽的影响[J].湖南中医药导报,2004,10(12)：54—55,59
[31]杨志波、欧阳恒、许斌竹黄颗粒剂Ⅱ号对银屑病患者β-内啡肽的影响中国中西医结合皮肤性病学杂志2003年第2卷第3期166-167。
[32]Werner S, Smola H. Paracrine regulation of keratinocyte proliferationand differentiationm. TrendsCenBiol,2001,11:143-146.
[33]Wu SX, Guo NR. Clinical observation on effect of tfiptolide tablet intreating patients with psoriasis vulgaris[J]. Chinese Journal of IntegrativeMedicine,2005, 11：147-1481。
[34]王砚宁,毕新岭,顾军,等.黄芩甙治疗银屑病的机制研究[J].中国中西医结合皮肤性病学杂志,2003,2(4)：209—211.
[35]毕新岭,王砚宁,顾军,等.黄芩甙对成纤维细胞iNOS表达的影响[J].中国中西医结合皮肤性病学杂志,2003,2(3)：152—154